10-Q: Mangoceuticals Faces Financial Hurdles Amidst Business Combination

Mangoceuticals, Inc. reported continued net losses and a significant accumulated deficit in its Q2 2026 filing, while also detailing a pending business combination with Nuclea Energy Inc. and management changes.

Summary

• Mangoceuticals, Inc. (MGRX) filed its Form 10-Q for the quarterly period ended June 30, 2026.
• The company reported a net loss of $1,312,931 for the three months ended June 30, 2026, and a net loss of $4,716,072 for the six months ended June 30, 2026.
• As of June 30, 2026, the company had an accumulated deficit of $45,363,283.
• The company's cash and cash equivalents decreased to $228,688 as of June 30, 2026, from $1,486,338 as of December 31, 2025.
• Mangoceuticals is not in compliance with Nasdaq's minimum bid price requirement and has been granted an extension until February 1, 2027, to regain compliance.
• A significant development is the pending Business Combination Agreement (BCA) with Nuclea Energy Inc., expected to result in Nuclea shareholders holding approximately 96% of the combined company's equity.
• The company's CEO, Jacob D. Cohen, is set to resign as CEO upon closing of the transaction and transition to President, with a severance package including $1.5 million in cash and 2 million shares of common stock.
• The company acknowledges substantial doubt about its ability to continue as a going concern due to its recurring losses and need for future funding.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to significant net losses, a substantial accumulated deficit, and ongoing concerns about the company's ability to continue as a going concern, despite a pending business combination.

Positives

• The company has entered into a Business Combination Agreement with Nuclea Energy Inc., which could provide a path for future growth and capital infusion.
• The company received $272,000 in June 2026 from a private placement subscription.
• The company is actively pursuing strategic alternatives to unlock and maximize shareholder value.
• Despite operational challenges, the company continues to market its men's wellness products and services.

Negatives

• Significant net losses were reported for both the three-month ($1,312,931) and six-month ($4,716,072) periods ended June 30, 2026.
• The company has a substantial accumulated deficit of $45,363,283 as of June 30, 2026.
• Cash and cash equivalents decreased significantly from $1,486,338 to $228,688 during the first six months of 2026.
• The company is not in compliance with Nasdaq's minimum bid price requirement and faces potential delisting if compliance is not achieved.
• The company's ability to continue as a going concern is in doubt, requiring substantial additional financing.
• The pending business combination with Nuclea Energy Inc. is expected to result in substantial dilution to existing shareholders, with former Nuclea shareholders anticipated to hold approximately 96% of the combined company's equity.
• The company faces regulatory risks related to its reliance on a related-party pharmacy operating under Section 503A of the FFD&C Act.
• The company is involved in a significant lawsuit against its former technology consulting firm, Clarity Ventures, Inc., seeking over $73 million in damages.

Risks

• The company is not in compliance with Nasdaq's minimum bid price requirement and faces potential delisting if compliance is not achieved by February 1, 2027.
• The company's ability to continue as a going concern is in doubt due to recurring net losses and the need for substantial future financing.
• The pending business combination with Nuclea Energy Inc. is subject to numerous closing conditions, including shareholder approval and regulatory approvals, and may not be completed.
• The business combination will result in substantial dilution to existing shareholders, with former Nuclea shareholders expected to hold approximately 96% of the combined company's equity.
• The company's reliance on a related-party pharmacy operating under Section 503A of the FFD&C Act exposes it to significant regulatory risk, including potential reclassification as a drug manufacturer.
• The company is involved in a lawsuit against Clarity Ventures, Inc., seeking over $73 million in damages, which could result in significant costs and potential adverse outcomes.
• The company's business strategy will fundamentally shift to nuclear energy technology following the business combination, introducing significant technology development, licensing, and execution risks.
• The company's common stock price may experience increased volatility due to the pendency of the transaction and the significant change in business strategy.

Future Outlook

The company anticipates needing additional funding to continue operations and execute its business plan, including the pending business combination with Nuclea Energy Inc. The success of the business combination and future funding efforts are critical for the company's survival and growth.

Management Comments

• Management acknowledges that the company's current capital resources are not expected to be sufficient for operations for the next 12 months and that additional funding will be required.
• Management believes that the pending business combination with Nuclea Energy Inc. represents a significant strategic move that could unlock and maximize shareholder value.
• Management is actively pursuing strategic alternatives to enhance shareholder value.
• Management has concluded that there is substantial doubt about the ability of the Company to continue as a going concern.

Industry Context

StockSavvy.ai notes that Mangoceuticals operates in the competitive men's wellness and telemedicine sector. The pending business combination with Nuclea Energy Inc., a company in the nuclear energy sector, signals a significant pivot in business strategy, moving away from its current focus.

Comparison to Industry Standards

• The company's financial performance, characterized by significant net losses and a negative going concern assessment, is not aligned with industry standards for established, profitable companies in the health and wellness sector.
• The substantial dilution expected from the business combination is a common, though often concerning, outcome in reverse mergers and SPAC transactions within the broader technology and energy sectors.
• The company's reliance on compounded drugs and telehealth platforms places it in a regulatory environment that is subject to increasing scrutiny, unlike companies operating solely with FDA-approved, manufactured pharmaceuticals.

Management Changes

Corporate Governance

Legal Proceedings

• The Company is involved in an arbitration action with FINRA initiated by Boustead, claiming fees for services not retained by the Company.
• The Company filed a lawsuit against Clarity Ventures, Inc. for failure to deliver a functional, HIPAA-compliant ERP and eCommerce platform, seeking over $73 million in damages.
• Clarity Ventures, Inc. has denied allegations and asserted counterclaims for alleged unpaid invoices.

Related Party Transactions

• Cost of revenues related party represents amounts paid to Epiq Scripts, a related party pharmacy.
• Amounts owed to related parties include $6,000 to the CFO and $44,944 in notes payable to the CEO as of June 30, 2026.
• Jacob Cohen, CEO, owns 49% of Mango & Peaches Corp., a subsidiary, and has 51% voting control through Series A Preferred Stock.
• The company entered into a Consulting Agreement with Muhammad Azfar, issuing 75,000 shares.
• The company entered into a Consulting Agreement with Gatorland Holdings, LLC, issuing 250,000 shares.
• The company entered into a Consulting Agreement with LSTM Holdings LLC, issuing 200,000 shares for an extension.
• The company entered into a Service Agreement with Greentree Financial Group, Inc., issuing 40,000 shares and owing $20,000 cash.
• Jacob Cohen received 2,000,000 bonus shares of common stock as part of a Release and Separation Agreement.

Stakeholder Impact

• Existing shareholders will experience substantial dilution due to the pending business combination, with former Nuclea shareholders expected to hold approximately 96% of the combined company's equity.
• The company's going concern status and potential Nasdaq delisting could negatively impact investor confidence and the liquidity of common stock.
• Employees, officers, and directors may face uncertainty regarding their roles due to anticipated management and board changes following the business combination.
• Customers, suppliers, and business partners may delay, modify, or terminate relationships due to the pending transaction and the shift in business strategy towards nuclear energy.

Next Steps

• Complete the Business Combination Agreement with Nuclea Energy Inc.
• Obtain necessary shareholder and regulatory approvals for the transaction.
• Secure a minimum of $15,000,000 in PIPE financing.
• Regain compliance with Nasdaq's minimum bid price requirement.
• Transition management and board of directors as per the business combination agreement.
• Continue marketing and developing men's wellness products while integrating the new business focus.

Key Dates

Recommendation

The company exhibits significant financial distress, including substantial net losses, a growing accumulated deficit, and a going concern warning. While the pending business combination offers a potential lifeline, the terms indicate extreme dilution for existing shareholders, and the company's core business faces regulatory and competitive challenges. The shift to a completely different industry (nuclear energy) adds considerable risk and uncertainty. The ongoing Nasdaq listing non-compliance further exacerbates the negative outlook.

Keywords

Mangoceuticals, Form 10-Q, Business Combination, Nuclea Energy, Going Concern, Nasdaq Compliance, Men's Wellness, Telemedicine